Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
Krystal Biotech launched Vyjuvek Gel (beremagene geperpavec), Japan’s first treatment for dystrophic epidermolysis bullosa (DEB), on October 22, the same day it was added to the NHI reimbursement list. At a briefing on October 21, Hiroshi Kasamoto, president of Krystal…
To read the full story
Related Article
- Listing OK’ed for Krystal’s Vyjuvek Gel, Japan’s First Topical Gene Therapy
October 16, 2025
- Japan to Apply Drug Pricing Rules for Krystal Gene Therapy: Chuikyo
August 28, 2025
- Krystal Biotech Snags Japan Nod for Vyjuvek as 1st Topical Gene Therapy
July 29, 2025
- Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
July 8, 2025
BUSINESS
- Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- J-TEC to Explore Regenerative Medicine Licensing Opportunities in Taiwan
August 19, 2026
- Shionogi to Effectively Scrap Mandatory Retirement from FY2027
August 19, 2026
- Chugai Out-Licenses Anti-Dengue Antibody AID351 to GSK
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…